INS and Hypoglycemia: The LAPTOP study has demonstrated that, for insulin-naïve patients, a regimen composed of once-daily insulin glargine (LANTUS®; sanofi-aventis, Frankfurt, Germany) plus oral antidiabetic drugs (OADs) is associated with better glycaemic control and reduced risk of hypoglycaemia compared with premixed insulin (4).